Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of QLC5508 versus investigator's choice chemotherapy in previously platinum-treated advanced extrapulmonary neuroendocrine carcinoma
CTR20263930Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of MHB088C in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Qilu Pharmaceutical. Started Oct 2026; status: active.
02
Drugs
MHB088C
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on CTR20263930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263930.